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REVIEW
Solving the Puzzle of Chronic Ischemic Mitral
Regurgitation
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MD; Sigurdur Ragnarsson, MD
Yale University School of Medicine, Section of Cardiac Surgery, New Haven, Connecticut
Chronic ischemic mitral regurgitation is a prevalent problem among patients following a my-
ocardial infarction. Until recently, the pathophysiology was poorly understood, resulting in
surgical strategies with suboptimal results and limited durability. The surgical approach has
evolved from revascularization alone to an additional mitral valve procedure, replacement,
or repair. When the valve was repaired, isolated annuloplasty was performed. The dilemma
that surgeons had when repairing a mitral valve was which type of ring to use and what
size. In all series with annuloplasty alone, the results were poor with very high recurrence
rates. The primary feature of ischemic mitral regurgitation is a prolapse of the anterior leaflet
at A3 ± A2. This prolapse can be caused by fibrotic elongation of the papillary muscle sup-
porting A3 ± A2 or tethering of P3 by a ballooning posterior left ventricular wall. Using a
technique that corrects this prolapse with Gore-Tex neochords, we have achieved excellent
results with effective and durable correction of the ischemic mitral regurgitation.
INTRODUCTION
Ischemic mitral regurgitation (IMR†) is
present in 10 percent to 20 percent of pa-
tients with coronary artery disease (CAD),
with a conservatively estimated prevalence
of 1.6 million to 2.9 million patients in the
United States alone [1]. Other authors be-
lieve this to be a gross underestimate and
have calculated that more than 5 million
Americans are afflicted with this condition
[2]. In spite of these numbers, relatively lit-
tle progress has been made toward effec-
tively treating this complicated condition.
There are no randomized trials addressing
IMR, and there is a lack of a unifying def-
inition throughout the literature. Many au-
thors have drawn conclusions regarding
IMR based upon studies that included pa-
tients with myxomatous MR and incidental
CAD.
One aspect of IMR that is well docu-
mented is the grave prognosis it portends.
Data from the Survival andVentricular En-
largement (SAVE) Study has shown that
patients who develop MR following a my-
ocardial infarction (MI) demonstrated a
significantly worse overall prognosis than
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points tested (MR vs. no MR: cardiovascular
mortality, 29 percent vs. 12 percent, p <
0.001; severe heart failure, 24 percent vs. 16
percent, p = 0.0153; and the combined end
point of cardiovascular mortality, severe
heart failure, or recurrent myocardial infarc-
tion, 47 percent vs. 29 percent, p < 0.0001)
[3].Astudy of 11,748 cardiac catheterization
patients showed a one-year mortality rate in
patients with severe IMR of 40 percent,
moderate IMR 17 percent, and mild IMR 10
percent [4].The one-year mortality rate was
6 percent in patients without IMR.
Finding a treatment modality for IMR
that significantly improves survival in a
durable fashion has eluded physicians for
decades.There is considerable disagreement
within the literature as to what approach
should be taken in this difficult patient pop-
ulation. Many authors have shown that
revascularization alone is sufficient [5,6],
whereas others favor surgically addressing
the valve itself in addition to revasculariza-
tion [7]. If the surgeon decides to perform a
valve-directed procedure at the time of coro-
nary artery bypass grafting surgery (CABG),
should the valve be replaced or repaired?
Two recent large-scale studies have tackled
this question, and the data supports repair of
the mitral valve when possible [8,9]. The
final question remaining is how to recon-
struct a valve that appears morphologically
intact. Dr. L. Henry Edmunds, Jr. has written
of IMR: “Most often the entire valve appears
normal … There is little to fix, yet the valve
leaks. … the valve is structurally normal; it
need not be replaced, but currently we do
not know how to fix it. …” [10].
The purpose of this paper is to review
the mechanisms of chronic IMR, the surgi-
cal techniques being utilized, and our own
surgical approach to this problem.
DEFINITIONS AND MECHANISMS
OF CHRONIC IMR
Borger et al. proposed the definition as
MR occurring more than one week after an
MI with (1) one or more left ventricular seg-
mentalwallmotionabnormalities;(2)signif-
icant coronary disease in the territory
supplying the wall motion abnormality; and
(3)structurallynormalMVleafletsandchor-
dae tendinae [1]. Other authors have used
less specific criteria. Grossi et al. considered
ischemic mitral insufficiency to be the pres-
ence of severe mitral incompetence (by
echocardiography or angiography) arising
from an ischemic process confirmed by the
intraoperative pathologic evaluation of the
valve [8]. The definition put forth by the
Toronto group, on the other hand, is ex-
tremely specific and includes mechanistic
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Table 1. Modified Carpentier Classification of Mitral Regurgitation
Type
Ia
Ib
IIa
IIb
IIc
IId
IIIa
IIIb
Leaflet Motion
Normal
Excessive
Restricted
Description
Annular dilation only
Leaflet perforation
Chordal elongation
Chordal rupture
PM infarction/elongation
PM rupture
Commisural or chordal fusion
Leaflet tethering by left ventricular dysfunction or
aneurysmschemes for the regurgitation. They defined
chronic IMR as occurring in patients with
CADandresultingfromPMinfarction,scar-
ring, dysfunction, or a delayed presentation
duetopartialruptureofaPMhead(typesIIc,
IId, and IV, Table 1) or leaflet tethering by
left ventricular dysfunction (type IIIb). An-
nular dilation alone (type Ia) was included
only in the absence of other features of de-
generative valve disease [11]. The authors
categorize the various forms of IMR accord-
ingtotheModifiedCarpentierClassification
(Table 1) that is based upon normal, exces-
sive, or restricted leaflet motion.
When discussing chronic IMR in the lit-
erature and attaching that label to a patient’s
condition, one should use a definition that is
as specific as possible in order to ensure the
exclusion of other etiologies for mitral re-
gurgitation (myxomatous, rheumatic, infec-
tious, or congenital).
The pathophysiology leading to chronic
IMR is a myocardial infarction that distorts
the papillary muscles. This usually occurs
with occlusion of the right or left dominant
circumflex coronary arteries, causing an in-
farction involving the posterior ventricular
wall and posterior PM [12]. The involve-
ment of the anterior PM is less common be-
cause of its dual blood supply from both the
left anterior descending coronary artery and
a diagonal or obtuse marginal coronary ar-
tery.
Following an MI, mitral regurgitation
has been documented by Doppler in up to 39
percent of patients [13]. Competency of the
mitral valve is dependent upon the coordi-
nated interaction between the leaflets, the
annulus, choradae tendinae, and the papil-
lary muscles (PM) [1]. A consistent finding
at surgery for IMR is the observation that
there is an overriding A3 ± A2 over the op-
posite leaflet, whether it is due to fibrotic
elongation of a PM or to leaflet tethering by
a ballooning infarcted wall. Therefore, the
common functional pathology in IMR is
prolapse of A3 ± A2. The mitral regurgita-
tion increases the left ventricular volume
and size. This dilates the annulus and in-
creases the regurgitant volume, and a vicious
cycle begins. Not only does the mitral annu-
lus dilate with ischemia, but its distinctive
saddle shape is flattened. This ischemia-in-
duced annular modulation was elegantly
demonstrated by Gorman et al. in a sheep
model using sonomicrometry array localiza-
tion that measured the three-dimensional
geometry of the mitral annulus. The authors
found an accentuation of the saddle shape
annulus during systole in normal subjects,
but during ischemia that caused mitral regur-
gitation, this accentuation was eliminated
[14]. Neither isolated PM dysfunction nor
annular dilation alone cause significant IMR
[1].
SURGICAL OPTIONS FOR
CHRONIC IMR
The first question when considering
surgical treatment for chronic IMR is to de-
termine if the etiology of the regurgitation is
ischemic. Transthoracic echocardiography
represents the most useful tool in establish-
ing the diagnosis. The presence of left ven-
tricular wall abnormalities or absence of
myxomatous or rheumatic leaflet pathology
leads to a high probability that ischemia is
the cause of the mitral regurgitation.The de-
cision to treat IMR should be based on pre-
operative transthoracic echocardiography
rather than intraoperative transesophageal
echocardiography because of the afterload
reduction induced by anesthesia [1,15].
Borger et al. have proposed lowering estab-
lished echocardiographic criteria for MR
when dealing with ischemic regurgitation
because of the associated worse long-term
prognosis. Specifically, they recommend
considering an effective regurgitant orifice
of more than 20 mm2 as severe in patients
with chronic IMR, as opposed to the classic
40 mm2 in organic mitral disease [1].
Once the diagnosis is established and a
decision made for operative revasculariza-
tion, the question becomes whether revascu-
larization alone is sufficient to treat the IMR.
Tolis et al. recently described clinical and
echocardiographic outcomes examined after
isolated CABG in 49 patients with ischemic
cardiomyopathy and 1+ to 3+ MR undergo-
ing surgical revascularization. The authors
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tion fraction (22.0 percent to 31.5 percent, p
< 0.05), New York Heart Association con-
gestive heart failure class (3.3 to 1.8, p <
0.05), and degree of MR (1.73 to 0.54, p <
0.05) with 50 percent five-year survival [5].
One limitation of the study was the rela-
tively high percentage of patients falling into
the 1+ MR category (37 percent) and low
percentage in the 3+ MR category (10 per-
cent). It is generally agreed that patients un-
dergoing CABG with moderate-to-severe
IMR (3+ to 4+) also should have a mitral
valve-directed procedure as part of the op-
eration [1]. The controversy lies in patients
with mild to moderate MR (1+ or 2+). Mul-
tiple studies have shown a progression of
mitral regurgitation and worse overall prog-
nosis in this patient population when CABG
alone was performed [16,7]. Exercise car-
diography is very helpful to determine the
significance of IMR in patients with 1+ to
2+ regurgitation on a resting echocardio-
gram.
If preoperative echocardiography sug-
gests that the mitral valve will have to be ad-
dressed directly, the surgeon must decide
whether to repair or replace the valve. Mitral
valve replacement had been the preferred
approach to chronic IMR prior to the pio-
neering work in mitral valve repair ofAlain
Carpentier. Historically, mitral valve re-
placement involved complete excision of the
valve leaflets together with the subvalvular
apparatus. Such methods were shown to
compromise left ventricular function [17].
Currently, preservation of the entire sub-
valvular apparatus is the preferred technique
[18]. Additional disadvantages of mitral
valve replacement include the requirement
for life-long anticoagulation if a mechanical
valve is used and poor durability of tissue
prostheses. The advantages of replacement
are primarily reliability and reproducibility
and should be considered in patients with
chronic IMR who have multiple comorbidi-
ties, complex regurgitant jets, or severe teth-
ering of both mitral valve leaflets [1].
Two large studies from respected mitral
valve surgery centers, NewYork University
Medical Center and the Cleveland Clinic
Foundation, compared the results of mitral
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Figure 1. Transesophageal echocardiogram showing a complex regurgitant jet in a patient
with IMR.repair vs. replacement for IMR. The results
in both studies have shown a perioperative
survival advantage in patients who have had
mitral valve repair. Nevertheless, the five-
year survival with either technique was only
50 percent [8,9].Additionally, any perioper-
ative advantage was lost in the most high-
risk patients [9]. The overwhelming
majority of mitral valve repair patients in
both series consisted of isolated ring annulo-
plasty.The underlying concept of ring annu-
loplasty is to undersize the ring to achieve
leaflet coaptation during systole. This con-
cept was promoted by Bolling et al. in the
treatment of severe MR associated with end-
stage cardiomyopathy [19]. In those pa-
tients, satisfactory results were obtained, but
unlike the patients with cardiomyopathy
who have intact papillary muscles, patients
with IMR have infarcted papillary muscles
and left ventricular walls. This causes dis-
tortion of the geometric relation between the
papillary muscles and, therefore, suboptimal
leaflet coaptation. In most patients, ring an-
nuloplasty reduces the MR grade back to the
level it was in the early stages after the my-
ocardial infarction, before the vicious cycle
produces left ventricular dilation. This ex-
plains why there is frequent recurrence of
MR following ring annuloplasty that ini-
tially produced good results in the early
postoperative period.
In another study from the Clevelend
Clinic Foundation, 585 patients with IMR
were treated with ring annuloplasty alone,
and the authors found that 28 percent of
those patients had redeveloped 3+ or 4+ MR
only six months after the operation [20].
Roshanali et al. [21] found a similar failure
rate of 24.4 percent following ring annulo-
plasty alone.They identified by multivariate
analysis that an interpapillary muscle dis-
tance of greater than 20 mm as measured on
preoperative echocardiography predicted
failure of annuloplasty alone and concluded
that this could be used as an index for deter-
mining whether MR might recur after sim-
ple annuloplasty. They proposed adding a
complementary procedure to the annulo-
plasty if the interpapillary muscle distance
is greater than 20 mm. A meticulous
echocardiography examination can, in most
cases, reveal that in addition to a central re-
gurgitant jet, there is a posteriorly directed
jet (Figure 1).
Cutting secondary chordae and reloca-
tion of the posterior papillary muscle are two
adjunctive techniques to ring annuloplasty.
Cutting secondary chordae removes the
chordae that are primarily responsible for
leaflet restriction in IMR [22]. Surgical relo-
cation of the posterior papillary muscle was
developed by Kron and associates [23] at the
University of Virginia. This relatively sim-
ple procedure involves passing a 3-0 prolene
suture twice through the fibrous portion of
the posterior papillary muscle tip and then
up through the adjacent mitral annulus just
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Figure 2.At left: Mitral valve after in-
sertion of annuloplasty ring demon-
strating a Gore-tex neochord to A3
portion of anterior leaflet in a patient
with IMR. Below: Mitral valve follow-
ing completion of ring annuloplasty
and neochord to A3 showing even
coaptation plane without prolapse.posterior to the right fibrous trigone.As the
prolene suture is tied, the posterior papillary
muscle tip is drawn closer to the annulus
with the final position determined by the
point at which leaflet coaptation occurs in
the plane of the mitral annulus.
In 1983, Dr. Alain Carpentier revolu-
tionized the treatment of mitral regurgita-
tion by introducing repair techniques that
addressed the function of the valve regard-
less of etiology [24]. The proposed tech-
niques, such as leaflet resection and leaflet
transposition, addressed the pathology of
the mitral valve when it involved excess
leaflet tissue. This was very successful in
the treatment of rheumatic and myxomatous
valves. He also proposed ring annuloplasty
in all cases of mitral regurgitation. In
chronic IMR, there is no excess tissue, and
only ring annuloplasty could be applied.
This operation was widely used, but led to
frequent recurrence of mitral regurgitation.
The underlying pathology in IMR is ante-
rior leaflet prolapse without excess tissue.
The recent application of Gore-Tex neo-
chords for myxomatous valve disease was
very well suited to the treatment of chronic
IMR, but was not applied. In our institution,
we have extensive experience with the
Gore-Tex neochord and have adopted its
use in IMR (Figure 2). In IMR, the dysfunc-
tion present is a prolapse of A3 ± A2, re-
gardless of the pathophysiology of the
myocardial infarction. Our experience with
neochords in the treatment of IMR dates
back to the year 2000. We analyzed our re-
sults with 14 patients who had moderate to
severe IMR and who underwent this type of
repair with CABG. The surgeries were per-
formed by the senior author (SWH). Fol-
low-up included echocardiography in all
patients. Thirteen of the 14 patients were
alive at a mean interval of 3.03 years from
surgery. The one death occurred at nine
months due to complications from pre-ex-
isting end-stage renal failure. Mitral regur-
gitation was minimal or absent in all
patients except one (moderate), with no pa-
tients requiring reoperation. There was a
statistically significant improvement in mi-
tral regurgitation grade, NYHA grade, and
ejection fraction following the operation.
These results compare favorably with recur-
rence rate and survival data quoted in the
literature [8,9,20,21].
CONCLUSIONS
Chronic IMR is a relatively common
condition among patients with CAD and has
a dismal prognosis. The medical treatment
of IMR is associated with a high mortality
rate, and traditional surgical techniques have
failed to improve upon the natural history of
the disease. Only recently has an increased
awareness emerged that the correction of
IMR should address the muscular pathology,
including the papillary muscle and left ven-
tricle. Our surgical approach addresses the
functional pathology of the valve and has led
to a significant improvement in the treat-
ment of this disease.
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